OncoMatch/Clinical Trials/NCT02215889
Partial Liver Segment 2/3 Transplantation Study
Is NCT02215889 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for colorectal cancer.
The patients will receive hepatectomy as a 2 stage procedure. In the first surgical procedure liver segments 2-3 are removed and liver donor segments 2-3 inserted. After growth of donor segments 2-3, the remaining liver segments of the recipient are removed. The patient will at this time have only donor liver tissue in place.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
All patients should have received at least 8 weeks of chemotherapy.
Cannot have received: palliative resection of primary CRC tumor
Palliative resection of primary CRC tumor.
Lab requirements
Blood counts
Hb >10g/dl, neutrophiles >1.0 (after any G-CSF), TRC >75
Kidney function
Creatinine <1.25 x upper normal level
Liver function
Bilirubin <2 x upper normal level, ASAT, ALAT <5 x upper normal level, Albumin above lower normal level
Satisfactory blood tests: Hb >10g/dl, neutrophiles >1.0 (after any G-CSF), TRC >75, Bilirubin<2 x upper normal level, ASAT,ALAT<5 x upper normal level, Creatinine <1.25 x upper normal level. Albumin above lower normal level.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify